Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

399 Press Releases
DateTitleCompany
07 Dec 16 Limited improvement in EGFR testing rates observed in new survey with approximately one in five advanced lung cancer patients still at risk of missing out on targeted therapy Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
29 Nov 16 Boehringer Ingelheim and China Southeast University collaborate to develop new treatment approaches for hearing loss Boehringer Ingelheim ,
Published by
PharmiWeb.com
22 Nov 16 Survey Reveals Most People Don't Know Heart Disease Is the No. 1 Killer of People with Type 2 Diabetes Boehringer Ingelheim and Eli Lilly and Company,
Published by
PR Newswire
27 Oct 16 Boehringer Ingelheim Named One of Science Magazine's Top Employers for the Twelfth Consecutive Year Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
26 Oct 16 Boehringer Ingelheim's adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study Boehringer Ingelheim,
Published by
PharmiWeb.com
25 Oct 16 Efficacy of Ofev® (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST Boehringer Ingelheim,
Published by
PharmiWeb.com
24 Oct 16 New Real-World Data Show Pradaxa® (dabigatran etexilate mesylate) Treatment Resulted in Less Use of All-Cause Healthcare Resources than Warfarin Treatment Boehringer Ingelheim ,
Published by
PharmiWeb.com
21 Oct 16 New Real-World Data Show Pradaxa® (dabigatran etexilate mesylate) Treatment Resulted in Less Use of All-Cause Healthcare Resources than Warfarin Treatment Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
18 Oct 16 Boehringer Ingelheim joins The Leukemia & Lymphoma Society in groundbreaking precision medicine approach to treating acute myeloid leukemia Boehringer Ingelheim Pharmaceuticals,
Published by
PR Newswire
12 Oct 16 New Support Program Provides Free Medicine and Resources for People Living with COPD Prescribed STIOLTO® RESPIMAT® (tiotropium bromide and olodaterol) Inhalation Spray Boehringer Ingelheim Pharmaceuticals,
Published by
PR Newswire
09 Oct 16 Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO Boehringer Ingelheim Pharmaceuticals,
Published by
PR Newswire
09 Oct 16 Overall survival data from LUX-Lung 7 head-to-head trial of Gilotrif® (afatinib) versus Iressa® (gefitinib) presented at ESMO Boehringer Ingelheim,
Published by
PR Newswire
30 Sep 16 Boehringer Ingelheim and Sarah Cannon Research Institute launch strategic collaboration to develop novel immune-oncology therapies Boehringer Ingelheim ,
Published by
PharmiWeb.com
29 Sep 16 Boehringer Ingelheim and Sarah Cannon Research Institute launch strategic collaboration to develop novel immune-oncology therapies Boehringer Ingelheim Pharmaceuticals,
Published by
PR Newswire
28 Sep 16 Boehringer Ingelheim boosts immune-oncology pipeline through collaboration with ViraTherapeutics Boehringer Ingelheim ,
Published by
PharmiWeb.com
28 Sep 16 Boehringer Ingelheim boosts immune-oncology pipeline through collaboration with ViraTherapeutics Boehringer Ingelheim,
Published by
PR Newswire
21 Sep 16 New survey reveals 9 out of 10 patients with IPF were happy with the way their doctor told them about their IPF diagnosis Boehringer Ingelheim,
Published by
Ogilvy Healthworld
09 Sep 16 Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease Boehringer Ingelheim ,
Published by
PharmiWeb.com
29 Jul 16 First Study Initiated to Evaluate the Effect of Ofev® Treatment on Biomarkers that may Predict IPF Progression Boehringer Ingelheim ,
Published by
PharmiWeb.com
27 Aug 16 Boehringer Ingelheim and Duke Clinical Research Institute Expand Collaboration to Create Largest Patient Registry for Idiopathic Pulmonary Fibrosis (IPF) Boehringer Ingelheim ,
Published by
PharmiWeb.com
29 Aug 16 ESC Congress 2016 Late Breaking Science Registry: Latest Data on Pradaxa® (dabigatran etexilate mesylate) Safety and Effectiveness Profile Show Low Rates of Bleeding and Stroke in NVAF Patients in Routine Clinical Care Boehringer Ingelheim ,
Published by
PharmiWeb.com
27 Jul 16 First Study Initiated to Evaluate the Effect of Ofev® Treatment on Biomarkers that may Predict IPF Progression Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
27 Jun 16 Sanofi and Boehringer Ingelheim Have Reached Definitive Agreements to Swap Sanofi’s Animal Health and Boehringer Ingelheim’s Consumer Healthcare Businesses Boehringer Ingelheim,
Published by
Business Wire
12 Jun 16 New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes Boehringer Ingelheim GmbH,
Published by
Business Wire
02 Jun 16 Boehringer Ingelheim launches ambitious ELUXA trial program to broadly investigate promising lung cancer compound olmutinib Boehringer Ingelheim,
Published by
PR Newswire
20 Jul 16 The European Stroke Organisation and Boehringer Ingelheim launch the “Angels Initiative”, a unique healthcare initiative to improve acute stroke care across Europe Boehringer Ingelheim,
Published by
PharmiWeb.com
27 Jun 16 New analysis of INPULSIS® trials demonstrates efficacy of OFEV® (nintedanib) across a range of IPF patients using broader diagnostic criteria Boehringer Ingelheim,
Published by
Business Wire
30 Jun 16 INMARKTM now enrolling: first study to evaluate the effect of OFEV® (nintedanib) on biomarkers reflecting the underlying fibrotic process in IPF patients Boehringer Ingelheim,
Published by
Business Wire
15 Jul 16 Boehringer Ingelheim and University of Dundee collaborate to develop new class of medicines Boehringer Ingelheim ,
Published by
PharmiWeb.com
22 Jul 16 Worldwide Clinical Trials Survey Reveals How Sponsors View the Role of CROs in Clinical Development Boehringer Ingelheim,
Published by
PharmiWeb.com
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.